Neuronutrition and Alzheimer's disease

Journal of Alzheimer's Disease

Volumn 19, Issue 4, 2010, Pages 1123-1139

  Ramesh, Balenahalli N ^a   Rao, T S Sathyanarayana ^b   Prakasam, Annamalai ^c   Sambamurti, Kumar ^c   Rao, K S Jagannatha ^a  

^a CENTRAL FOOD TECHNOLOGICAL RESEARCH INSTITUTE   (India)

^b JSS MEDICAL COLLEGE   (India)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Antioxidants; Caloric restriction; Diet; Homocysteine; Lipid; Neurodegeneration; Nutrients; Oxidative stress; Polyphenols; Vitamins

Indexed keywords

ALCOHOL; ANTIOXIDANT; METAL ION; POLYPHENOL; SATURATED FATTY ACID; UNSATURATED FATTY ACID; VITAMIN;

ALZHEIMER DISEASE; CHELATION; DEMENTIA; DIET; DIETARY INTAKE; ENVIRONMENTAL FACTOR; HEREDITY; HUMAN; MENTAL DEFICIENCY; NEUROPROTECTION; NUTRITIONAL DEFICIENCY; PRIORITY JOURNAL; REVIEW; SPICE; WINE;

EID: 77950362845     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2010-1312     Document Type: Review

References (200)

1. Kalaria RN, Maestre GE, Arizaga R, Friedland RP, Galasko D, Hall K,. Luchsinger JA, Ogunniyi A, Perry EK, Potocnik F, Prince M, Stewart R,Wimo A, Zhang ZX, Antuono P (2008) Alzheimer's disease and vascular dementia in developing countries: prevalence, management, and risk factors. Lancet Neurol 7, 812-826.
2. LeeVM(2001) Tauists and beta-aptists united -well almost!. Science 293, 1446-1447.
3. Selkoe DJ (2001) Alzheimer's disease results from the cerebral accumulation and cytotoxicity of amyloid beta-protein. J Alzheimers Dis 3, 75-80.
4. WilquetV, StrooperB(2004) Amyloid-beta precursor protein processing in neurodegeneration. Curr Opin Neurobiol 14, 582-588.
5. Gasior M, Rogawski MA, Hartman AL (2006) Neuroprotective and disease-modifying effects of the ketogenic diet. Behav Pharmacol 17, 431-439.
6. Lau FC, Shukitt-Hale B, Joseph JA (2007) Nutritional intervention in brain aging: reducing the effects of inflammation and oxidative stress. Subcell Biochem 42, 299-318.
7. Dosunmu R,Wu J, Basha MR, Zawia H (2007) Environmental and dietary risk factors in Alzheimer's disease. Expert Rev Neurother 7, 887-900.
8. Hooijmans CR, Kiliaan AJ (2008) Fatty acids, lipid metabolism and Alzheimer pathology. Eur J Pharmacol 585, 176-196.
9. Luchsinger JA, Tang MX, Shea S, Mayeux R (2002) Caloric intake and the risk of Alzheimer disease. Ach Neurol 59, 1258-1263.
10. Panza F, Capurso C, Solfrizzi V(2008) Alcohol use, thiamine deficiency, and cognitive impairment. JAMA299, 2853-2854.
11. Kalmijn S, Feskens EJ, Launer LJ, Kromhout D (1997) Polyunsaturated fatty acids, antioxidants, and cognitive function in very old men. Am J Epidem 145, 33-41.
12. Grant WB (1998) The APOE-epsilon4 allele and Alzheimer disease among African Americans, Hispanics, and whites. JAMA 280, 1662-1663.
13. Launer LJ, Brock DB (2004) Population-based studies of AD: message and methods: an epidemiologic view. Stat Med 23, 191-197.
14. Strachan MW (2003) Insulin and cognitive function. Lancet 362, 1253.
15. Mayeux R, Stern Y, Ottman R, Tatemichi TK, Tang MX, Maestre G, Tycko NC, Schofield PW, Tang M, Marder K, Bell K, Dooneief G, Lantigua R, Wilder D, Gurland B, Stern, Mayeux R (1995) Consistency of clinical diagnosis in a community-based longitudinal study of dementia and Alzheimer's disease. Neurology 45, 2159-2164.
16. Abellan G, Van Kan, Rolland Y, Nourhashemi F, Coley N, Andrieu S, Vellas B (2009) Cardiovascular disease risk factors and progression of Alzheimer's disease. Dement Geriatr Cogn Disord 28, 240-246
17. Luchsinger JA, Mayeux R (2004) Dietary factors and Alzheimer's disease. Lancet Neurology 3, 579-587.
18. Ott A, Slooter AJ, Hofman A, van Harskamp F, Witteman JC, Van Broeckhoven C, van Duijn CM, Breteler MM(1998) Smoking and risk of dementia and Alzheimer's disease in a population-based cohort study: the Rotterdam Study. Lancet 351, 1840-1843.
19. Merchant C, Tang MX, Albert S, Manly J, Stern Y, Mayeux R (1999) The influence of smoking on the risk of Alzheimer's disease. Neurology 52, 1408-1412.
20. Honing LS, Tang MX, Albert S, Costa R, Luchsinger J, Manly J, Stern Y, Mayeux R (2003) Stroke and the risk of Alzheimer disease. Arch Neurol 60, 1707-1712.
21. Vermeer SE, Prins ND, denHeijer T, Hofman A, Koudstaal PJ, Breteler MM (2003) Silent brain infarcts and the risk of dementia and cognitive decline. N Eng J Med 348, 1215-1222.
22. Mayeux R, Stern Y, Ottman R, Tatemichi TK, Tang MX, Maestre G, Ngai C, Tycko B, Ginsberg H (1993) The Apolipoprotein epsilon 4 allele in patients with Alzheimer's disease. Ann Neurol 34, 752-754.
23. Aksenov MY, Aksenova MV, Butterfield DA, Geddes JW, Markesbery WR (2001) Protein oxidation in the brain in Alzheimer's disease. Neuroscience 103, 373-383.
24. Markesbery WR (1997) Oxidative stress hypothesis in Alzheimer's disease. Free Radic Biol Med 23, 134-147.
25. Markesbery WR, Carney JM (1999) Oxidative alterations in Alzheimer's disease. Brain Pathol 9, 133-146.
26. Sayre L, Smith MA, Perry G (2001) Chemistry and biochemistry of oxidative stress in neurodegenerative disease. Curr Med Chem 8, 721-738.
27. Butterfield D, Castegna A, Pocernich C, Drake J, Scapagnini G, Calabrese V (2002) Nutritional approaches to combat oxidative stress in Alzheimer's disease. J Nutr Biochem 13, 444-461.
28. Grant WB, Campbell A, Itzhaki RF, Savory J (2002) The significance of environmental factors in the etiology of Alzheimer's disease. J Alzheimers Dis 4, 179-189.
29. Gillenwater JY, Grayhack JT, Howards SS, Duckett JW (1991) Adult and Pediatric Urology. Mosby Year Book, St. Louis, p. 2366.
30. Rovio S, Kåreholt I, Helkala EL, Viitanen M, Winblad B, Tuomilehto J, Soininen H, Nissinen A, Kivipelto M (2005) Leisure-time physical activity at midlife and the risk of dementia and Alzheimer's disease. Lancet Neurol 4, 705-711.
31. Sun M-K, Alkon DL (2006) Links between Alzheimer's disease and diabetes. Drugs Today 42, 481-489
32. Leibson CL, Rocca WA, Hanson A, Cha R, Kokmen E, O'Brien PC, Palumbo PJ (1997) The risk of dementia among persons with diabetes mellitus: a population-based cohort study. Ann N Y Acad Sci 826, 422-427.
33. Peila R, Rodriguez BL, Launer LJ (2002) Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia Aging Study. Diabetes 51, 1256-1262.
34. Lee CK, Weindruch R, Prolla TA (2000) Gene-expression profile of the ageing brain in mice. Nature Genet 25, 294-297.
35. Morgan TE, Xie Z, Goldsmith S, Yoshida T, Lanzrein AS, Stone D, Rozovsky I, Perry G, Smith MA, Finch CE (1999) The mosaic of brain glial hyperactivity during normal ageing and its attenuation by food restriction. Neuroscience 89, 687-699.
36. Olgun A, Akman S, Serdar MA, Kutluay T (2002) Oxidative phosphorylation enzyme complexes in caloric restriction. Exp Gerontol 37, 639-645.
37. Bruce-Keller AJ, Umberger G, McFall R, MattsonMP(1999) Food restriction reduces brain damage and improves behavioral outcome following excitotoxic and metabolic insults. Ann Neurol 45, 8-15.
38. Mattson MP (2003) Gene-diet interactions in brain aging and neurodegenerative disorders. Ann Inter Med 139, 441-444.
39. Mattson MP (2000) Emerging neuroprotective strategies for Alzheimer's disease: dietary restriction, telomerase activation, and stem cell therapy. Exp Gerontol 35, 489-502.
40. Engelhart MJ, Geerlings MI, Ruitenberg A, VanSwieten JC, Hofman A, Witteman JC, Breteler MM (2002) Diet and risk of dementia: Does fat matter?: The Rotterdam Study. Neurology 59, 1915-1921.
41. Gustafson D, Rothenberg E, Blennow K, Steen B, Skoog I (2003) An 18-year follow-up of overweight and risk of Alzheimer disease. Arch Inter Med 163, 1524-1528.
42. Grant WB (2004) Obesity and Alzheimer disease: roles of diet and genetics. Arch Inter Med 164, 109-110.
43. Mattson MP, Chan SL, DuanW(2002) Modification of brain aging and neurodegenerative disorders by genes, diet, and behavior. Physiol Review 82, 637-672.
44. Lee J, Duan W, Long JM, Ingram DK, Mattson MP (2000) Dietary restriction increases the number of newly generated neural cells, and induces BDNF expression, in the dentate gyrus of rats. J Mol Neurosci 15, 99-108.
45. Logroscino G, Marder K, Cote L, Tang MX, Shea S, Mayeux R (1996) Dietary lipids and antioxidants in Parkinson's disease: a population-based, case-control study. Ann Neurol 39, 89-94.
46. Duan W, Guo Z, Mattson MP (2001) Brain-derived neurotrophic factor mediates an excitoprotective effect of dietary restriction in mice. J Neurochem 76, 619-626.
47. Yu ZF, Mattson MP (1999) Dietary restriction and 2- deoxyglucose administration reduce focal ischemic brain damage and improve behavioral outcome: evidence for a preconditioning mechanism. J Neurosci Res 57, 830-839.
48. Lee J, Duan W, Mattson MP (2002) Evidence that brainderived neurotrophic factor is required for basal neurogenesis and mediates, in part, the enhancement of neurogenesis by dietary restriction in the hippocampus of adult mice. J Neurochem 82, 1367-1375.
49. Duan W, Guo Z, Jiang H, Ware M, Li XJ, Mattson MP (2003) Dietary restriction normalizes glucose metabolism and BDNF levels, slows disease progression, and increases survival in huntingtin mutant mice. Proc Natl Acad Sci U S A 100, 2911-2916.
50. Hock C, Heese K, Hulette C, Rosenberg C, Otten U (2000) Region-specific neurotrophin imbalances in Alzheimer dis ease: decreased levels of brain-derived neurotrophic factor and increased levels of nerve growth factor in hippocampus and cortical areas. Arch Neurol 57, 846-851.
51. Howells DW, Porritt MJ, Wong JY, Batchelor PE, Kalanins R, Hughes AJ, Donnan GA (2000) Reduced BDNF mRNA expression in the Parkinson's disease substantia nigra. Exp Neurol 166, 127-135.
52. Hunt ND, Hyun DN, Allard JS, Minor K, Mattson MP, Ingram DK, Cabo R (2006) Bioenergetics of aging and calorie restriction. Aging Res Rev 5, 125-143.
53. Qin W, Chachich M, Lane M, Roth G, Bryant M, de Cabo R, Ottinger MA, Mattison J, Ingram D, Gandy S, Pasinetti GM (2006) Calorie restriction attenuates Alzheimer's disease type brain amyloidosis in Squirrel monkeys (Saimiri sciureus). J Alzheimers Dis 10, 417-422.
54. Halagappa VK, Guo Z, Pearson M, Matsuoka Y, Cutler RG, Laferla FM (2007) intermittent fasting and caloric restriction ameliorate age-related behavioral deficits in the tripletransgenic mouse model of Alzheimer's disease. Neurobiol Dis 26, 212-220
55. Gillette-Guyonnet, Vellas B (2008) Caloric restriction and brain function. Curr Opin Clin Nutr Metab Care 11, 686-692.
56. Wu P, Shen Q, Dong S, Xu Z, Tsien JZ, Hu Y (2008) Calorie restriction ameliorates neurodegenerative phenotypes in forebrain-specific presenelin-1and presenelin-2 double knockout mice. Neurbiol Aging 29, 1502-1511.
57. Levenson CW, Rich NJ (2007), Eat less, live longer? New insights into role of calorie restriction in the brain. Nutr Rev 65, 412-415.
58. Blandford G, Watkins LB, Mulvihil MN (1998) Assesing abnormal feeding behavior in dementia: a taxonomy and initial findings. In Weight Loss and Eating Behaviour in Alzheimer's Patients: Research and Practice in Alzheimer Disease, Vellas B, Riviere S, Fitten J (eds). SERDI, Paris, pp. 47-64.
59. Riviere S, Gillette-Guyonnet S, Andrieu S, Nourhashemi F, Lauque S, Cantet C, Salva A, Frisoni G, Vellas B (2002) Cognitive function and caregiver burden: predictive factors for eating behaviour disorders in Alzheimer's disease. Inter J Geriatr Psych 17, 950-955.
60. Shatenstein B, Kergoat MJ, Reid I (2007) Poor nutrient intakes during 1-year follow-up with community-dwelling older adults with early-stage Alzheimer dementia compared to cognitively intact matched controls. J Am Diet Assoc 107, 2091-2099.
61. Luchsinger JA, Gustafson DR (2009) Adiposity and Alzheimer's disease. Curr Opin Clin Nutr Metab Care 12, 15-21.
62. Bassett CN, Montine TJ (2003) Lipoproteins and lipid peroxidation in Alzheimer's disease. J Nutr Health Aging 7, 24-29.
63. Puglielli L, Tanzi RE, Kovacs DM (2003) Alzheimer's disease: the cholesterol connection. Nat Neurosci 6, 345-351.
64. Jarvik GP, Wijsman EM, Kukull WA, Schellenberg GD, Yu C, Larson EB (1995) Interactions of Apolipoprotein E genotype, total cholesterol level, age, and sex in prediction of Alzheimer's disease: a case-control study. Neurology 45, 1092-1096.
65. Petanceska SS, DeRosa S, Sharma A, Diaz N, Duff K, Tint SG, Refolo LM, Pappolla M (2003) Changes in apolipoprotein E expression in response to dietary and pharmacological modulation of cholesterol. J Mol Neurosci 20, 395-406.
66. Marshall JA, Kamboh MI, Bessesen DH, Hoag S, Hamman RF, Ferrell RE (1996) Associations between dietary factors and serum lipids by apolipoprotein E polymorphism. Am J Clin Nutr 63, 87-95.
67. Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, Myers RH, PericakVance MA, Risch N, vanDuijn CM (1997) Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 278, 1349-1356.
68. Farrer LA, Friedland RP,Bowirrat A,Waraska K,Korczyn A, BaldwinCT(2003) Genetic and environmental epidemiology of Alzheimer's disease in arabs residing in Israel. J Mol Neurosci 20, 207-212.
69. Petot GJ, Traore F, Debanne SM, Lerner AJ, Smyth KA, Friedland RP (2003) Interactions of apolipoprotein E genotype and dietary fat intake of healthy older persons during mid-adult life. Metabolism 52, 279-281.
70. Lopez-Miranda J, Ordovas JM, Mata P, Lichtenstein AH, Clevidence B, Judd JT, Schaefer EJ (1994) Effect of apolipoprotein E phenotype on diet-induced lowering of plasma low density +-+lipoprotein cholesterol. J Lipid Res 35, 1965-1975.
71. Campos H, D'Agostino M, Ordovas JM (2001) Gene-diet interactions and plasma lipoproteins: role of apolipoprotein E and habitual saturated fat intake. Gene Epidem 20, 117-128.
72. Hu FB, Willett WC (2002) Optimal diets for prevention of coronary heart disease. JAMA 288, 2569-2578.
73. Lim GP, Calon F, Morihara T, Yang F, Teter B, Ubeda O, Salem Jr N, Frausty SA, ColeCM(2005)Adiet enriched with omega-3 fatty acid docosahexaenoic acid reduces amyloid burden in an aged Alzheimer's mouse model. J Neurosci 25, 3032-3040.
74. Calon F, Lim GP,Yang F, Morihara T, Teter B, Ubeda O, Rostaing P, Triller A, Salem Jr N, Ashe KH, Frautschy SA, Cole GM (2004) Docosahexaenoic acid protects from dendritic pathology in an Alzheimer's disease mouse mode. Neuron 2, 633-645.
75. Kitjka K, Puskas LG, Zvara A, Hacker LJ, BarceloCoblijn G, Yeo YK, Farkas T (2002) The Role of n-3 polyunsaturated fattyacids in the brain: modulation of rat brain gene expression by dietary expression by dietary n-3 fatty acids. Proc Natl Acad Sci U S A 99, 2619-2624.
76. Puskas LG, Kitajka K, Nyakas C, Barcelo-Coblijn G, Farksa T (2003) Short-term administration of omega-3 fattyacids from fish oil results in increased transthyretin transcription in old rat hippocampus. Pro Natl Acad Sci U S A 100, 1560-1565.
77. Schroeder F,Woodford JK, Kavecansky J,Wood WG, Joiner C (1995) Cholesterol domains in biological membranes. Mol Membrane Biol 12, 113-119.
78. Porter JA, Young KE, Beachy PA (1996) Cholesterol modification of hedgehog signaling proteins in animal development. Science 274, 255-259.
79. Yeagle PL (1991) Modulation of membrane function by cholesterol. Biochimie 73, 1303-1310.
80. Mitchell DC, Straume M, Miller JL, Litman BJ (1990) Modulation of metarhodopsin formation by cholesterol-induced ordering of bilayer lipids. Biochemistry 29, 9143-9149.
81. Brown MS, Goldstein JL (1997) The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 89, 331-340.
82. Rouser G, Kritchevsky G, Yamamoto A, Baxter CF (1972) Lipids in the nervous system of different species as a function of age: brain, spinal cord, peripheral nerve, purified whole cell preparations, and subcellular particulates: regulatory mechanisms and membrane structure. Adv Lipid Res 10, 261-360.
83. Sakakihara Y, Volpe JJ (1985) Dolichol in human brain: regional and developmental aspects. J Neurochem 44, 1535-1540.
84. Roth GS, Joseph JA, Mason RP (1995) Membrane alterations as causes of impaired signal transduction in Alzheimer's disease and aging. Trends Neurosci 18, 203-206.
85. Igbavboa U, Avdulov NA, Schroeder F,WoodWG(1996) Increasing age alters transbilayer fluidity and cholesterol asymmetry in synaptic plasma membranes of mice. J Neurochem 66, 1717-1725.
86. Lutjohann D, Breuer O, Ahlborg G, Nennesmo I, Siden A, Diczfalusy U, Bjorkhem I (1996) Cholesterol homeostasis in human brain: evidence for an age-dependent flux of 24Shydroxycholesterol from the brain into the circulation. Proc Natl Acad Sci U S A 93, 9799-9804.
87. Reiss AB, Siller KA, Rahman MM, Chan ESL, Ghiso J, de Leon MJ (2004) Chlolesterol in neurologic disorders of the elderly: stroke and Alzheimer's disease. Neurobiol Aging 25, 977-989.
88. Mason RP, Shoemaker WJ, Shajenko L, Chambers TE, Herbette GL(1992) Evidence for changes in the Alzheimer's disease brain cortical membrane structure mediated by cholesterol. Neurobiol Aging 13, 413-419.
89. Jarvik GP, Austin MA, Fabsitz RR, Auwerx J, Reed T, Christian JC, Deeb S (1994) Genetic influences on agerelated change in total cholesterol, low density lipoproteincholesterol, and triglyceride levels: longitudinal Apolipoprotein E genotype effects. Genet Epidemiol 11, 375-384.
90. Koudinov AR, Koudinova NV (2001) Essential role for cholesterol in synaptic plasticity and neuronal degeneration. FASEB J 15, 1858-1860.
91. Puglielli L, Konopka G, PackChung E, Ingano LA, Berezovska O, THyman B, Chang TY, Tanzi RE, Kovacs DM (2001) Acyl-coenzyme A: cholesterol acyltransferase modulates the generation of the amyloid beta-peptide. Nat Cell Biol 3, 905-912.
92. Bodovitz S, Klein WL (1996) Cholesterol modulates alpha secretase clevage of amyloid precursor protein. J Biol Chem 271, 4436-4440.
93. Nunan J, Small GW (2002) Proteolytic processing of the amyloid-beta protein precursor of Alzheimer's disease. Essays Biochem 38, 37-49.
94. Cole SL, Grudzien A, Manhart IO, Kelly BL, Oakley H, Cole RV (2005) Statins cause intracellular accumulation of amyloid precursor protein, -secretase-cleaved fragments, and amyloid -peptide via an isoprenoid-dependent mechanism. J Biol Chem 280, 18755-18770.
95. Zhou Y, Suram A, Venugopal C, Prakasam A, Lin S, Su Y, Baolin Li B, Paul SM, Sambamurti K (2008) Geranylgeranyl pyrophosphate stimulates-secretase to increase the generation of AΒ and APP-CTF. FASEB J 22, 47-54.
96. Refolo L, Pappolla M, Malester B, LaFrancois J, Wang R, Tint G, Sambamurti K, Bryant-Thomas T, Duff K (2000) Hypercholesterolemia accelerates amyloid pathology in a transgenic mouse model for Alzheimer's disease amyloidosis. Neurobiol Dis 7, 321-331.
97. Granholm AC, Bimonte-Nelson HA, Moore AB, Nelson ME, Freeman LR, Sambamurti K (2008) Effects of a saturated fat and high cholesterol diet on memory and hippocampal morphology in the middle-aged rat. J Alzheimers Dis 14, 133-145.
98. Patil S, Chan C (2005) Palmitic and stearic fatty acids induce Alzheimer-like hyperphosphorylation of tau in primary rat cortical neurons. Neurosci Lett 384, 288-293.
99. Panza F, Solfrizzi V, Colacicco AM, D'Introno A, Capurso C, Torres F, Parig AD, Capurso S, Capurso A (2004) Mediterranean diet and cognitive decline. Public Health Nutr 7, 959-963.
100. Reaven E, Cao L, Azhar S (1994) Effect of age on cholesterol uptake and utilization by rat adrenals: II. Lipoproteins from young and old rats. Mech Ageing Dev 77, 27-41.
101. Arendash GW, Jensen MT, SalemJr N, Hussei N, Cracchiolo J, Dickson A et al. (2007) A diet high in omega-3 fatty acids does not improve orprotect cognitive performance in Alzheimer's transgenic mice. Neuroscience 149, 286-302.
102. Pappolla MA, Bryant-Thomas TK, Herbert D, Pacheco J, Garcia F M, Manjon M,. Girones X, Henry TL, Matsubara E, Zambon D, Wolozin B, Sano M, Cruz-Sanchez, Thal LJ, Petanceska SS, Refolo LM (2003) Mild hypercholesterolemia is an early risk factor for the development of Alzheimer amyloid pathology. Neurology 61,199-205.
103. Mielke MM, Zandi PP, Sjögren M, Gustafson D, Ö stling S, Steen B, Skoog I (2005) High total cholesterol levels in late life associated with a reduced risk of dementia. Neurology 64, 689-1695
104. Sambamurti K, Granholm A-C, Kindy MS, Bhat NR, Greig NH, Lahiri DK, Mintzer JE (2005) Cholesterol and Alzheimer's Disease: Clinical and experimental models suggest interactions of different genetic, dietary and environmental risk factors. Curr Drug Targets 5, 517-528.
105. Rottkamp CA, Nunomura A, Hirai K, Sayre LM, Perry G, Smith MA (2000) Will antioxidants fulfill their expectations for the treatment of Alzheimer disease? Mech Ageing Dev 116, 169-179.
106. Smith MA, Harris PLR, Sayre LM, Perry G (1997) Iron accumulation in Alzheimer's disease is a source of redoxgenerated free radicals. Pro Natl Acad Sci U S A 94, 9866-9868.
107. Good PF, Peril D, Bierer LM, Schmeidler (1992) Selective accumulation of aluminium and iron in neurofibrillary tangles of Alzheimer's disease: a laser microprobe (LAMA study). Neurology 31, 286-292.
108. Muma NA, Singer SM (1996) Aluminum -induced neuropathology: transient changes in microtubule-associated proteins. Neurotoxicol Teratol 18, 679-690.
109. Garruto RM, Fukatsu R, Yanagihara R, Gajdusek DC, Hook G, Fiori CE (1984) Imaging of calcium and aluminum in neurofibrillary tangle-bearing neurons in parkinsonism-dementia of Guam. Proc Natl Acad Sci U S A 81, 1875-1879.
110. Oteiza PI (1994) A mechanism for the stimulatory effect of aluminium on iron induced lipid peroxidation. Arch Biochem Biophys 308, 374-379.
111. Castellani RJ, Smith MA, Nunomura A, Harris PLR, Perry G (1999) Increased redox active iron in Alzheimer's disease failure of the copper binding protein ceruloplasmin? Free Radic Biol Med 26, 1508-1512.
112. Rao KSJ, Rao RV, Shanmugavelu P, Menon RB (1999) Trace elements in Alzheimer's disease brain: Anew hypothesis. Alzheimer's Rep 2, 241-246.
113. Sparks DL, Schreurs BG (2003) Trace amounts of copper in water induce Β-amyloid plaques and learning deficits in a rabbit model of Alzheimer's disease. Proc Natl Acad Sci U S A 100, 11065-11069.
114. Lahiri DK, Zawia NH, Greig NH, Sambamurti K, Maloney B (2008) Early life events may trigger biochemical pathways for Alzheimer's disease:the "LEARn" model. Biogerontology 9, 375-379.
115. Hegde ML, Bharathi P, Suram A, Venugopal V, Jagannathan R Poddar P, Srinivas P, Sambamurti K, Rao KSJ, Scancar J, Messori L, Zecca L, Zatta P (2009) Challenges associated with metal chelation therapy in Alzheimer's disease. J Alzheimers Dis 17, 457-468
116. Butterfield DA, Castegna A, Drake J, Scapagnini G, Calabrese V (2002) Vitamin E and neurodegenerative disorders associated with oxidative stress. Nutr Neurosci 5, 229-239.
117. Ascherio A (2000) Antioxidants and stroke. Am J Clin Nutr 72, 337-338.
118. Hirvonen T, Virtamo J, Korhonen P, Albanes D, Pietinen P (2000) Intake of flavonoids, carotenoids, vitamins C and E, and risk of stroke in male smokers. Stroke 31, 2301-2306.
119. Zandi PP, Anthony JC, Khachaturian AS, Stone SV, Gustafson D, Tschanz JT, Norton MC, WelshBohmer KA, Breitner JC (2004) Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: the Cache County Study. Arch Neurol 61, 82-88.
120. Kedar NP (2003) Can we prevent Parkinson's and Alzheimer's disease. J Postgrad Med 49, 236-245.
121. Luchsinger JA, Tang MX, Shea S, Mayeux R (2003) Antioxidant vitamin intake and risk of Alzheimer disease. Arch Neurol 60, 203-208.
122. Cavallini L, Bindoli A, Siliprandi N (1978) Comparative evaluation of antiperoxidative action of silymarin and other flavonoids. Pharm Res Commun 10, 133-136.
123. Fusco D, Colloca G, Monaco MRL, Cesari M (2007) Effects of antioxidant supplementation on the aging process. Clin Interv Aging 2, 377-387.
124. Joseph JA, Shukitt-Hale B, Denisova NA, Prior RL, Cao G, Martin A, Taglialatela G, Bickford PC (1998) Long-term dietary strawberry, spinach, or vitamin E supplementation retards the onset of age-related neuronal signal-transduction and cognitive behavioral deficits. J Neurosci 18, 8047-8055.
125. Morris MC, Evans DA, Tangney CC, Bienias JL,Wilson RS, Aggarwal NT, Scherr PA (2005) Relation of the tocopherol forms to incident Alzheimer disease and to cognitive change. Am J Clin Nutr 81, 508-514.
126. Peterson RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, Galasko D, Jin S, Kaye J, Levey A, Pfeiffer E, Sano M, Christopher H, Dyck V, Thal LJ (2005) Vitamin E and Donepezil for the treatment of mild cognitive impairment. N Engl J Med 353, 2379-2388.
127. Young KW, Greenwood CE (2001) Shift in diurnal feeding patterns in nursing home residents with Alzheimer's disease. J Gerontol A Biol Sci Med Sci 56, 700-706.
128. Sumien N, Forster MJ, Sohal RS (2003) Supplementation with vitamin E fails to attenuate oxidative damage in mice. Exp Gerentol 38, 699-704.
129. Kontush K. Schekatolina S (2004) Vitamin E in neurodegenerative disorders: Alzheimer's disease. Ann N Y Acad Sci 1031, 249-262.
130. Seshadri S, Wolf PA (2003) Homocysteine and the brain: vascular risk factor or neurotoxin? Lancet Neurol 2, 11.
131. He K, Merchant A, Rimm EB, Rosner BA, Stampfer MJ, Willett WC, Ascherio A (2004) Folate, vitamin B6, and B12 intakes in relation to risk of stroke among men. Stroke 35, 169-174.
132. Leboeuf R (2003) Homocysteine and Alzheimer's disease. J Am Diet Assoc 103, 304-307.
133. Clarke R, Smith AD, Jobst KA, Refsum H, Sutton L, Ueland PM (1998) Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease. Arch Neurol 55, 1449-1555.
134. Mattson MP (2000) Emerging neuroprotective strategies for Alzheimer's disease: dietary restriction, telomerase activation, and stem cell therapy. Exp Gerontol 35, 489-502.
135. KrumanII TS, Kumaravel A, LohaniWA, Pedersen RG, Cutler Y, Kruman N, Haughey J, Lee M, Evans, Mattson MP (2002) Folic acid deficiency and homocysteine impair DNA repair in hippocampal neurons and sensitize them to amyloid toxicity in experimental models of Alzheimer's disease. J Neurosci 22, 1752-1762.
136. Baydas G, Kutlu S, Naziroglu M, Canpolat S, Sandal S, Ozcan M, Kelestimur H (2003) Inhibitory effects of melatonin on neural lipid peroxidation induced by intracerebroventricularly administered homocysteine. J Pineal Res 34, 36-39.
137. Kruman II, Culmsee C, Chan SL, Kruman Y, Guo Z, Penix L, Mattson MP (2000) Homocysteine elicits a DNA damage response in neurons that promotes apoptosis and hypersensitivity to excitotoxicity. J Neurosci 20, 6920-6926.
138. Fuso A, Seminara L, Rosaria A, Cavallaro, Anselmi FD, Scarpa S (2005) S-adenosylmethionine/homocysteine cycle alternations modify DNAmethylation status with consequent deregulation of PS1 and BACE and beta-amyloid production. Mol Cell Neurosci 28, 195-204.
139. Fuso A, Nicolia V, Cavallaro RA, Ricceri L, D'Anselmi F, Coluccia P, Calamandrei G, Scarpa S (2008) B-vitamin deprivation induces hyperhomocysteinemia and brain S-adenosylhomocysteine, depletes brain Sadenosylmethionine, and enhances PS1 and BACE expression and amyloid-beta deposition in mice. Mol Cell Neurosci 37, 731-746
140. Pacheco-Quinto J, Rodriguez de Turco EB, DeRosa S, Howarda A, Cruz-Sanchezc A, Sambamurti K, Refoloe L, Petanceska S, Pappolla MA (2006) Hyperhomocysteinemic Alzheimer's mouse model of amyloidosis shows increased brain amyloid Β peptide levels. Neurobiol Dis 22, 651-656.
141. Jang JH, Surh YJ (2003) Protective effect of resveratrol on beta-amyloid-induced oxidative PC12 cell death. Free Radic Biol Med 34, 1100-1110.
142. Mandel S. AmitT, Bar O,YoudimMB(2007) Iron dydregulation in Alzheimers disease: multimodal brain permeable iron chelating drugs possessing neuroprotective -neurorescue and amyloid precursor protein-processing regulatory activities as therapeutic agents. Prog Neurobiol 82, 348-360.
143. Van Acker SA, Vanden Berg DJ, Tromp MN, Griffioen DH, Van Bennekom WP, Vander Vijgh WJ, Bast A (1996) Structural aspects of antioxidant activity of flavonoids. Free Radic Biol Med 20, 331-342.
144. Levites Y, Weinreb O, Maor G, Youdim MBH, Mandel S (2001) Green tea polyphenol(-) epigallocatechin-3-gallate prevents N-methyl-4-phenyl-1,2,3,6- tetrahydropyridine-induceddopaminergicneurodegener ation. J Neurochem 78, 1073-1082.
145. Wang J, Ho L, Zhao W, Ono K, Rosenberg C, Chen L et al. (2008) Grape derived ployphenolics preventAΒ oligomerization and attenuate cognitive deterioration in a mouse model of Alzheimer'd disease. J Neurosci 28, 6388-6392.
146. Salah N, Miller NJ, Paganga G,TigburgL,BolwelGP, RiceEvans C (1995) Polyphenolic flavanols as scavengers of aqueous phase radicals and as chain -breaking antioxidants. Arch Biochem Biophys 322, 339-346.
147. Morel I, Lescoat G, Cogrel P, Sergent O, Pasdeloup N, Brissot P, Cillard P, Cillard J (1998) Antioxidant and iron chelating activities of the flavonoids carechin,quercetin and diosmetin on iron-loaded rat hepatocyte cultures. Biochem Pharmocol 45, 13-19.
148. Thompson M, Williams CR, Elliot GE (1976) Stability of flavonoids complexes of copper (II) and flavonoids antioxidant activity. Ann Chim Acta 85, 375-381.
149. Levites Y, Amit T, Youdim MB, Mandel S (2002) Involvement of protein kinase C activation and cell survival/ cell cycle genes in green tea polyphenol (-)-epigallocatechin 3- gallate neuroprotective action. J Biol Chem 277, 30574-30580.
150. Rezai-Zadeh K, Shytle D, Sun N, Mori T, Hou H, Jeanniton D, Ehrhart J, Townsend K, Zeng J, Morgan D, Hardy J, Town T, Tan J (2005) Green tea epigallocatechin-3-gallate (EGCG) modulates amyloid precursor protein cleavage and reduces cerebral amyloidosis in Alzheimer transgenic mice. J Neurosci 25, 8807-8814.
151. RuitenbergA, vanSwieten JC,Witteman JC, Mehta KM, van- Duijn CM, Hofman A, Breteler MM (2002) Alcohol consumption and risk of dementia: the Rotterdam Study. Lancet 359, 281-286.
152. Mukamal KJ, Kuller LH, Fitzpatrick AL, Longstreth Jr WT, Mittleman MA, Siscovick DS (2003) Prospective study of alcohol consumption and risk of dementia in older adults. JAMA 289, 1405-1413.
153. Galanis DJJoseph, C, Masaki KH, Petrovitch H, Ross GW, White L (2000) Longitudinal study of drinking and cognitive performance in elderly Japanese American men: the Honolulu-Asia Aging Study. Am J Public Health 90, 1254-1259.
154. Luchsinger JA, Mayeux R (2004) Cardiovascular risk factors and Alzheimer's disease. Curr Atheroscle Rep 6, 261-266.
155. Truelsen T, Thudium D, Gronbaek M (2002) Copenhagen City Heart Study, Amount and type of alcohol and risk of dementia: the Copenhagen City Heart Study. Neurology 59, 1313-1319.
156. Jaatinen P, Riikonen J, Riihioja P, Kajander O, Hervonen (2003) A Interaction of aging and intermittent ethanol exposure on brain cytochrome c oxidase activity levels. Alcohol 29, 91-100.
157. Sacco RL, Elkind M, BodenAlbala B, Lin IF, Kargman DE,. Hauser WA, Shea S, Paik MC (1999) The protective effect of moderate alcohol consumption on ischemic stroke. JAMA 281, 53-60.
158. Lindsay D, Laurin R, Verreault R, Hebert B, Helliwell, Hill GB, McDowell I (2002) Risk factors for Alzheimer's disease: a prospective analysis from the Canadian Study of Health and Aging. Am J Epidem 156, 445-453.
159. Orgogozo JM, Dartigues JF, Lafont S, Letenneur L, Commenges D, Salamon R, Renaud S, Breteler MB (1997) Wine consumption and dementia in the elderly: a prospective community study in the Bordeaux area. Review Neurol 153, 185-192.
160. Savaskan E, Olivieri G, Meier F, Seifritz E, WirzJustice A, MullerSpahn F R (2003)Wine ingredient resveratrol protects from beta-amyloid neurotoxicity. Gerontology 49, 380-383.
161. Han YS, Zheng WH, Bastianetto S, Chabot JG, Quirion R (2004) Neuroprotective effects of resveratrol against betaamyloid- induced neurotoxicity in rat hippocampal neurons: involvement of protein kinase C. Bringham. J Pharmacol 141, 997-1005.
162. Marambaud P, Zhao H, Davies P (2005) Resveratrol promotes clearance of Alzheimer's disease amyloid-beta peptides. J Biol Chem 280, 37377-37382.
163. deVrij FM, Fischer DF, vanLeeuwen FW, Hol EM (2004) Protein quality control in Alzheimer's disease by the ubiquitin proteasome system. Prog Neurobiol 74, 249-270.
164. Guarente L (2001) SIR2 and aging-the exception that proves the rule. Trend Genet 17, 391-392.
165. Araki T, Sasaki Y, Milbrandt J (2004) Increased nuclear NAD biosynthesis and SIRT1 activation prevent axonal degeneration. Science 13, 1010-1013.
166. Hoult J, Moroney MA, Paya M (1994) Actions of flavonoids and coumarins on lipoxygenase and cyclooxygenase. Method Enzymol 234, 443-454.
167. Resnick B, Junlapeeya P (2004) Falls in a community of older adults: findings and implications for practice. App Nurs Res 17, 81-91.
168. Wenzel E, Somoza V (2005) Metabolism and bioavailability of trans-resveratrol. Mol Nutr Food Res 49, 472-481.
169. Gescher AJ, StewardWP(2003) Relationship between mechanisms, bioavailibility, and preclinical chemopreventive efficacy of resveratrol: a conundrum. Cancer Epidemiol Biomarkers Prev 12, 953-957.
170. Baur JA, Sinclair DA (2006) Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 5, 493-506.
171. Walle T, Hsieh F, Delegge MH, Jr JEO, Walle UK (2004) High absorption but
172. Soleas GJ, Angelini M, Grass L, Diamandis EP, Goldberg DM (2001) Absorption of trans -resveratrol in rats. Methods Enzymol 335, 145-154.
173. Vingtdeux V, Dreses-Werringloer U, Zhao H, Davies P, Marambaud P (2008) Therapeutic potential of resveratrol in Alzheimer's disease. BMC Neurosci 9, S6.
174. Karuppagounder SS, Pinto JT,XuH, Chen HL, BealMF, Gibson GE (2008) Dietary supplementation with resveratrol reduces plaque pathology in a transgenic model of Alzheimer's disease. Neurochem Int 54, 111-118.
175. Ono K, Condron MM, Ho L, Wang J, Zhao W, Pasinetti GM (2008) Effects of grape seed-derived ployphenols on Amyloid beta protein self-assembly and cytotoxicity. J Biol Chem 283, 32176-32187.
176. Kelloff GJ, Crowell JA, Steele VE, Lubet RA, Malone WA, BooneCW,Kopelovich L, HawkET, Lieberman R, Lawrence JA, Ali I, Viner JL, Sigman CC (2000) Progress in cancer chemoprevention: development of diet-derived chemopreventive agents. J Nutr 130, 467S-471S.
177. Ganguli M, Chandra V, Kamboh MI, Johnston JM, Dodge HH, Thelma BK, Juyal RC, Pandav R, Belle S, DeKosky ST (2000) Apolipoprotein E polymorphism and Alzheimer disease: The Indo-US Cross-National Dementia Study. Arch Neurol 57, 824-830.
178. Dheen ST, Kaur C Ling EA (2007) Microglial activation and its implications in the brain diseases. Curr Med Chem 14, 1189-1197.
179. Rogers J, Webster S, Lue LF, Brachova L, Civin WH, Emmerling M, Shivers B, Walker D, McGeer (1996) Inflammation and Alzheimer's disease pathogenesis. Neurobiol Aging 17, 681-686.
180. Breitner JC, Welsh KA, Helms MJ, Gaskel PC, Gau BA, Roses AD, Pericak-Vance MA, Saunders AM (1995) Delayed onset of Alzheimer's disease with nonsteroidal antiinflammatory and histamine H2 blocking drugs. Neurobiol Aging 16, 523-530.
181. Bjorkman D (1998) Nonsteroidal anti-inflammatory drugassociated toxicity of the liver, lower gastrointestinal tract, and esophagus. Am J Med 2, 17-21.
182. McGettigan P, Henry D (2000) Current problems with nonspecific COX inhibitors. Curr Pharmocol Design 6, 1693-1724.
183. MartinAragon S, Benedi JM, Villar AM (1997) Modifications on antioxidant capacity and lipid peroxidation in mice under fraxetin treatment. J Pharm Pharmacol 49, 49-52.
184. Sreejayan, Rao MN (1997) Nitric oxide scavenging by curcuminoids. J Pharm Pharmacol 49, 105-107.
185. Frautschy SA, HuW, Kim P, Miller SA, Chu T, HarrisWhite ME, ColeGM(2001) Phenolic anti-inflammatory antioxidant reversal of AΒ-induced cognitive deficits and neuropathology. Neurobiol Aging 22, 993-1005.
186. Lim GP, Chu T, Yang F, Beech W, Frautschy SA, Cole GM (2001) The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J Neurosci 21, 8370-8377.
187. Kumar A, Singh A (2008) Possible nitric oxide modulation in protective effect of Curcumin (Curcumin longa, Zingiberaceae) against sleep pdeprivation induced behavioural alterations and oxidative damage in mice. Phytomedicine 15, 577-586.
188. Ono K, Hasegawa K, Yoshiike Y, Takashima A, Yamada M, Naik H (2002) Nordihydroguaiaretic acid potently breaks down pre-formed Alzheimer's beta-amyloid fibrils in vitro. J Neurochem 81, 434-440.
189. Rajeswari A (2006) Curcumin protects mouse brain from oxidative stress caused by 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine. Eur Rev Med Pharmacol Sci 10, 157-161.
190. Kumar A, Naidu PS, Seghal N, Padi SS (2007) Effect of curcumin on intracerebroventricular colchicine-induced cognitive impairment and oxidative stress in rats. J Med Food 10, 486-494.
191. Daniel S, Limson JL, Dairm A, Watkinson GM, Daya S (2004) Through metal binding, curcumin protects against lead induced lipid peroxidation in rat brain homogenates and against lead induced tissue damage in rat brain. J Inorg Biochem 98, 266-275.
192. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, SmallGW, Roses AD, Haines JL, Pericak-Vance MA (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261, 921-923.
193. Hofman A, Ott A, Breteler MM, Bots ML, Slooter AJ, van Harskamp F, van Duijn CN, Van Broeckhoven C, Grobbee DE (1997) Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study. Lancet 349, 151-154.
194. Hara RO, Yesavage JA, Kraemer HC, Mauricio M, Friedman LF, MurphyJr GM (1998) The APOE epsilon4 allele is associated with decline on delayed recall performance in community-dwelling older adults. J Am Geriatr Soc 46, 1493-1498.
195. Caselli RJ, GraffRadford NR, Reiman EM, Weaver A, Osborne D, Lucas J, Uecker A, Thibodeau SN (1999) Preclinical memory decline in cognitively normal apolipoprotein E-epsilon4 homozygotes. Neurology 53, 201-207.
196. Greenwood CE, Tam C, Chan M, Young KWH, Binns MA, Reekum RM (2005) Behavioural disturbances, not cognitive deterioration, are associated with altered good selection in seniors with Alzheimer's disease. J Gerontol A Biol Sci Med Sci 60, 499-505.
197. Joseph JA, Shukitt-Hale B, Willis LM (2009) Grape juice, berries, and walnuts affect brain aging and behavior. J Nutr 139, 1813S-7S.
198. Oken BS, Storzbach DM, Kaye JA (1998) The efficacy of Ginkgo biloba on cognitive function in Alzheimer disease. Arch Neurol 55, 1409-1415
199. Joshi H, Parle M (2006) Nardostachys jatamansi improves learning and memory in mice. J Med Food 9, 113-118
200. Vasudevan M, Parle M (2007) Effect of Anwala churna (Emblica officinalis GAERTN): an ayurvedic preparation on memory deficit rats. Yakugaku Zasshi 12, 71701-71707.